



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
CORPORATION FINANCE

May 6, 2020

Michael W. Nall
President and Chief Executive Officer
Biocept, Inc.
5810 Nancy Ridge Drive
San Diego, CA 92121

Re: Biocept, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed April 20, 2020
File No. 001-36284

Dear Mr. Nall:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Charles Bair